Institut Curie: Breast Neoplasms trials

The registry lists 33 Breast Neoplasms studies with Institut Curie as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 3Phase 2 8Phase 3 6Phase 4 1No phase 17(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)RecruitingNCT07491380Not applicable
• Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut CurieRecruitingNCT07357311
• Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2
• Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)RecruitingNCT06459791Not applicable
• ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsRecruitingNCT06195709Phase 3
• Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerRecruitingNCT05955170Phase 2
• Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.RecruitingNCT05439005Phase 3
• "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedNCT06067061Phase 1/2
• Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerTerminatedNCT05932667Phase 2
• Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of TreatmentCompletedNCT05634395Not applicable
• Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant ChemotherapyCompletedNCT05011721Not applicable
• Study Evaluating Hot Flashes in Hormone Sensitive Breast CancerCompletedNCT04775043
• Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast CancerTerminatedNCT04720729Phase 2
• Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer. (KDOGCOV)CompletedNCT04541537Not applicable
• Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast CancerTerminatedNCT04469205Not applicable
• MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer SurgeryCompletedNCT04327063Phase 3
• Transcutaneous Breast Cancer Diagnosis by Canine OdorologyCompletedNCT04217109Not applicable
• Breast Cancer Risk After Diagnostic Gene SequencingCompletedNCT04145817Not applicable
• Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast CancerCompletedNCT03703557Not applicable
• Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized TrialCompletedNCT02839473Phase 3
• Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), NEOELASTOCompletedNCT02834494Not applicable
• A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)CompletedNCT02831634Not applicable
• Optimizing the Care Pathways of Patients Treated for Operable Breast.CompletedNCT02813317
• MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer SurgeryCompletedNCT02408393Phase 3
• Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast CancerTerminatedNCT02250118Phase 1
• Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.CompletedNCT01975142Phase 2
• Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)TerminatedNCT01956552Not applicable
• Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast CancersStatus unknownNCT01710605Phase 3
• Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisCompletedNCT01373710Phase 1/2
• Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast CancerCompletedNCT00898014
• Study of Tumor and Blood Samples From Women With Breast CancerStatus unknownNCT00897728
• Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast CancerStatus unknownNCT00875355Phase 2
• Chlorhydrate of Ropivacaine and Breast Cancer SurgeryCompletedNCT00370240Phase 4